Sign In
Get Clay Free →

Suggestions

    Brett Ewald

    SVP of Development and Corporate Strategy at DNAtrix

    Brett Ewald is an experienced biotechnology executive with over 15 years of expertise in developing oncology drugs within the pharmaceutical, biotech, and academic sectors.

    During his career, Brett has been involved in the clinical development of BRAFTOVI and PIQRAY, two approved drugs for oncology treatment.

    He has a remarkable track record of raising over $45 million in both dilutive and non-dilutive funding for various projects and initiatives.

    Brett's strengths lie in strategic planning, corporate collaborations, business development, fundraising, negotiation, novel trial design, technology assessment, and organizational leadership.

    His educational background includes a Bachelor of Science and Bachelor of Arts in Biology and Economics from Villanova University, as well as a Ph.D. in Pharmacology from The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.

    Currently, Brett serves as the Senior Vice President of Development and Corporate Strategy at DNAtrix, building on his previous roles as Vice President of Development and various leadership positions at Novartis Oncology.

    His earlier experiences include roles as a Postdoctoral Fellow and Graduate Research Assistant at MD Anderson Cancer Center, showcasing his deep-rooted involvement in the field of oncology research and drug development.

    Brett Ewald
    Add to my network

    Location

    San Diego, California